Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664

FGF-21 as a novel metabolic regulator

Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125

Pathogenesis of Liver Fibrosis

Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809

Lipid Droplets and Cellular Lipid Metabolism

Walther, T. C., & Farese, R. V. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061009-102430 · Cited by 1,701

Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21

Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504

Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States

Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495

FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis

Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077

Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

de Urturi, D. S., Buqué, X., Porteiro, B., Folgueira, C., Mora, A., Delgado, T. C., Prieto‐Fernández, E., Olaizola, P., Gómez‐Santos, B., Apodaka‐Biguri, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28749-z · Cited by 49

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Loomba, R. S., Kowdley, K. V., Rodriguez, J., Kim, N. J., Alvarez, A. M., Morrow, L., Jeglinski, B. I., Clawson, A., Chowdhury, S. K., Bain, G., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00067-6 · Cited by 47

Macrophage Signaling Pathways in Health and Disease: From Bench to Bedside Applications

Chi, Y., Jiang, H., Yin, Y., Zhou, X., Shao, Y., Li, Y., & Rao, J. (2025) · MedComm · doi:10.1002/mco2.70256 · Cited by 54

Hepatic hormone FGF21 and its analogues in clinical trials

Shao, W., & Jin, T. (2021) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.08.005 · Cited by 49

Role of hepatokines in non-alcoholic fatty liver disease

Ke, Y., Xu, C., Lin, J., & Li, Y. (2019) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2019-0029 · Cited by 46

Linking liver metabolic and vascular disease via bile acid signaling

Fiorucci, S., & Distrutti, E. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.10.005 · Cited by 48

FGF21 alleviates acute liver injury by inducing the SIRT1‐autophagy signalling pathway

Yang, X., Jin, Z., Lin, D., Shen, T., Zhang, J., Li, D., Wang, X., Zhang, C., Lin, Z., Li, X., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17144 · Cited by 45

Hyperlipidemia and hepatitis in liver-specific CREB3L3 knockout mice generated using a one-step CRISPR/Cas9 system

Nakagawa, Y., Oikawa, F., Mizuno, S., Ohno, H., Yagishita, Y., Satoh, A., Osaki, Y., Takei, K., Kikuchi, T., Han, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27857 · Cited by 44

Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases

Yi, H. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.39 · Cited by 43

Liver-derived FGF21 is essential for full adaptation to ketogenic diet but does not regulate glucose homeostasis

Watanabe, M., Singhal, G., Fisher, F. M., Beck, T. C., Morgan, D. A., Socciarelli, F., Mather, M. L., Risi, R., Bourke, J., Rahmouni, K., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02124-3 · Cited by 44

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease

Raptis, D. D., Mantzoros, C., & Polyzos, S. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s352008 · Cited by 31

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40

The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics

Eftekhari, A., Arjmand, A., Asheghvatan, A., Švajdlenková, H., Šauša, O., Abiyev, H., Ahmadian, E., Smutok, O. V., Khalilov, R. I., Kavetskyy, T. S., et al. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.674786 · Cited by 41

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 43

Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B0AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases

Yadav, A., Shah, N., Tiwari, P. K., Javed, K., Cheng, Q., Aidhen, I. S., & Bröer, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00140 · Cited by 39

Effect of circulating exosomes derived from normal-weight and obese women on gluconeogenesis, glycogenesis, lipogenesis and secretion of FGF21 and fetuin A in HepG2 cells

Afrisham, R., Sadegh‐Nejadi, S., Meshkani, R., Emamgholipour, S., & Paknejad, M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00540-4 · Cited by 39

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

Gallego‐Durán, R., Ampuero, J., Maya‐Miles, D., Pastor‐Ramírez, H., Montero‐Vallejo, R., Rivera‐Esteban, J., Álvarez‐Amor, L., Pareja, M. J., Rico, M. C., Millán, R., et al. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12534 · Cited by 35

Emerging Structure–Function Paradigm of Endocrine FGFs in Metabolic Diseases

Luo, Y., Ye, S., Li, X., & Lu, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.002 · Cited by 37

Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target

Liu, W., Xie, D.-M., Zhu, G., Huang, G., Lin, Y.-Q., Wang, L., Shi, K., Hu, B., Braddock, M., Chen, Y., et al. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.997711 · Cited by 38

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Le, C. T., Nguyen, G., Park, S. Y., Choi, D. H., & Cho, E.-H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192146 · Cited by 35

Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance

Maida, A., Zota, A., Vegiopoulos, A., Appak‐Baskoy, S., Augustin, H. G., Heikenwälder, M. F., Herzig, S., & Rose, A. J. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.03.027 · Cited by 34

Acute hyperenergetic, high-fat feeding increases circulating FGF21, LECT2, and fetuin-A in healthy men

Willis, S. A., Sargeant, J. A., Yates, T., Takamura, T., Takayama, H., Gupta, V., Brittain, E., Crawford, J., Parry, S. A., Thackray, A. E., et al. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz333 · Cited by 34

Pharmacotherapy for Nonalcoholic Fatty Liver Disease

Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35

Modulation of energy balance by fibroblast growth factor 21

Ramos, D. C., & Aguilar-Salinas, C. A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0023 · Cited by 36

Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers

Sui, Y., & Chen, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76924 · Cited by 33

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

González‐Rodríguez, Á., Valdecantos, M. P., Rada, P., Addante, A., Barahona, I., Rey, E., Pardo, V., Ruíz-Cañas, L., Laiglesia, L. M., Moreno-Aliaga, M. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.10.008 · Cited by 35

Magnetic-Assisted Treatment of Liver Fibrosis

Levada, K. V., Omelyanchik, A. S., Rodionova, V. V., Weiskirchen, R., & Bartneck, M. (2019) · Cells · doi:10.3390/cells8101279 · Cited by 33

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease

Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 33

Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective

Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R., & Navik, U. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106426 · Cited by 32

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges

Tian, H., Zhang, S., Liu, Y., Wu, Y., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054583 · Cited by 33

FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk

CHAFFIN, A. T. B., Larson, K. R., Huang, K.-P., Wu, C.-T., Nadejda, G., Fang, Y., Jayakrishnan, D., Sauza, K. A. S., Sims, L. C., Mohajerani, N., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155848 · Cited by 31

Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis

Li, G., Chen, H.-Q., Shen, F., Smithson, S. B., Shealy, G. L., Ping, Q., Liang, Z., Han, J., Adams, A. C., Li, Y., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000433 · Cited by 30

Oligonucleotide therapies for nonalcoholic steatohepatitis

Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 32

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease

Fiorucci, S., Biagioli, M., Baldoni, M., Ricci, P., Sepe, V., Zampella, A., & Distrutti, E. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916465 · Cited by 30

Potential therapeutic strategies for MASH: from preclinical to clinical development

Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31

The role of FGF21 in type 1 diabetes and its complications

Zhang, J., Weng, W., Wang, K., Lu, X., Cai, L., & Sun, J. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25026 · Cited by 30

The mitochondrial integrated stress response: A novel approach to anti-aging and pro-longevity

Wang, X., & Zhang, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102603 · Cited by 29

Fibroblast growth factor 21 and exercise-induced hepatic mitochondrial adaptations

Fletcher, J. A., Linden, M. A., Sheldon, R. D., Meers, G. M.-E., Morris, E. M., Butterfield, A. M., Perfield, J. W., Thyfault, J. P., & Rector, R. S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00355.2015 · Cited by 28

Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

AlNafea, H. M., & Korish, A. A. (2021) · PPAR Research · doi:10.1155/2021/5558731 · Cited by 28

Peonidin-3-O-Glucoside from Purple Corncob Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Mitochondrial and Lysosome Functions to Reduce Oxidative Stress and Inflammation

Hao, R., Shan, S., Yang, D., Zhang, H., Sun, Y., & Li, Z. (2023) · Nutrients · doi:10.3390/nu15020372 · Cited by 28

Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L. A., Aller, R., Khan, A., García‐Monzón, C., Arias, M., Miele, L., et al. (2021) · Advanced Science · doi:10.1002/advs.202004168 · Cited by 26

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 26

Hepatocyte β‐Klotho regulates lipid homeostasis but not body weight in mice

Kobayashi, K., Tanaka, T., Okada, S., Morimoto, Y., Matsumura, S., Manio, M. C. C., Inoue, K., Kimura, K., Yagi, T., Saito, Y., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-274449 · Cited by 27

Effect of circulating glucagon and free fatty acids on hepatic FGF21 production in dairy cows

Caixeta, L. S., Giesy, S. L., Krumm, C. S., Perfield, J. W., Butterfield, A. M., Schoenberg, K. M., Beitz, D. C., & Boisclair, Y. R. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00197.2017 · Cited by 29

Short-Chain Fatty Acid Production and Functional Aspects on Host Metabolism

Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00002-8 · Cited by 29

Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects

Watanabe, H., Miyahisa, M., Chikamatsu, M., Nishida, K., Minayoshi, Y., Takano, M., Ichimizu, S., Kobashigawa, Y., Morioka, H., Maeda, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.036 · Cited by 24

Endocrine Fibroblast Growth Factors in Relation to Stress Signaling

Shimizu, M., & Sato, R. (2022) · Cells · doi:10.3390/cells11030505 · Cited by 25

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Puengel, T., & Tacke, F. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230115 · Cited by 24

A sirtuin 1/MMP2 prognostic index for myocardial infarction in patients with advanced coronary artery disease

Doulamis, I. P., Tzani, A. I., Konstantopoulos, P. S., Samanidis, G., Georgiopoulos, G. A., Toutouzas, K. P., Perrea, D. N., & Perreas, K. G. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.086 · Cited by 23

Alcohol ingestion induces pancreatic islet dysfunction and apoptosis via mediation of FGF21 resistance

Yang, B. C., Wu, S. Y., & Leung, P. S. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.129 · Cited by 22

Fibroblast growth factor 21: A “rheostat” for metabolic regulation?

She, Q.-Y., Bao, J., Wang, H.-Z., Liang, H., Huang, W., Wu, J., Zhong, Y.-W., Ling, H., Li, A., & Qin, S.-L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155166 · Cited by 22

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis

Qiu, H., Song, E., Hu, Y., Li, T., Ku, K. C., Wang, C., Cheung, B. M. Y., Cheong, L. Y., Wang, Q., Wu, X., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.07.012 · Cited by 22

Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non‐obese HIV‐infected patients

Praktiknjo, M., Djayadi, N., Mohr, R. U., Schierwagen, R., Bischoff, J., Dold, L., Pohlmann, A., Schwarze‐Zander, C., Wasmuth, J., Boesecke, C., et al. (2019) · Liver International · doi:10.1111/liv.14107 · Cited by 22

Tracing Key Molecular Regulators of Lipid Biosynthesis in Tuber Development of Cyperus esculentus Using Transcriptomics and Lipidomics Profiling

Wang, L., Jing, M., Ahmad, N., Wang, Y., Wang, Y., Li, J., Li, X., Liu, W., Wang, N., Wang, F., et al. (2021) · Genes · doi:10.3390/genes12101492 · Cited by 21

The implication of hepatokines in metabolic syndrome

Esfahani, M., Baranchi, M., & Goodarzi, M. T. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.06.027 · Cited by 24

The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms

Xu, B., Shen, T., Chen, L., Xia, J., Zhang, C., Wang, H., Yu, M., & Lei, T. (2017) · Medical Science Monitor · doi:10.12659/msm.900033 · Cited by 21

Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets

Chu, Y., Yang, S., & Chen, X. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108844 · Cited by 21

FGF21 prevents low-protein diet-induced renal inflammation in aged mice

Fang, H., Ghosh, S., Sims, L. C., Stone, K. P., Hill, C. M., Spires, D. R., Ilatovskaya, D. V., Morrison, C. D., Gettys, T. W., & Stadler, K. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00107.2021 · Cited by 20

Fibroblast growth factor-21 (FGF21) administration to early-lactating dairy cows. II. Pharmacokinetics, whole-animal performance, and lipid metabolism

Caixeta, L. S., Giesy, S. L., Krumm, C. S., Perfield, J. W., Butterfield, A. M., & Boisclair, Y. R. (2019) · Journal of Dairy Science · doi:10.3168/jds.2019-16696 · Cited by 20

Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy

Valdecantos, M. P., Ruíz-Cañas, L., Pardo, V., Castro‐Sánchez, L., García‐Monzón, C., Lanzón, B., Rupérez, F. J., Barbas, C., Naylor, J., Trevaskis, J. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33949-z · Cited by 18

Evaluation of Browning Agents on the White Adipogenesis of Bone Marrow Mesenchymal Stromal Cells: A Contribution to Fighting Obesity

Maio, G. D., Alessio, N., Demirsoy, İ. H., Peluso, G., Perrotta, S., Monda, M., & Bernardo, G. D. (2021) · Cells · doi:10.3390/cells10020403 · Cited by 19

Hepatic CEACAM1 Over-Expression Protects Against Diet-Induced Fibrosis and Inflammation in White Adipose Tissue

Lester, S. G., Russo, L., Ghanem, S. S., Khuder, S. S., DeAngelis, A. M., Esakov, E. L., Bowman, T. A., Heinrich, G., Al–Share, Q. Y., McInerney, M. F., et al. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00116 · Cited by 19

Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression

Ma, F., Liu, Y., Hu, Z., Xue, Y., Liu, Z., Cai, G., Su, W., Zheng, Z., Xia, F., Yan, X., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000042 · Cited by 19

Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance

Eder, K., Geßner, D. K., & Ringseis, R. (2021) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-021-00621-y · Cited by 18

Transcriptome Comparison Reveals the Difference in Liver Fat Metabolism between Different Sheep Breeds

Li, T., Jin, M., Fei, X., Yuan, Z., Wang, Y., Quan, K., Wang, T., Yang, J., He, M., & Wei, C. (2022) · Animals · doi:10.3390/ani12131650 · Cited by 16

A human laboratory study on the link between alcohol administration and circulating fibroblast growth factor 21 (FGF21) in individuals with alcohol use disorder

Farokhnia, M., Wang, T., Jourdan, T., Godlewski, G., Farinelli, L. A., Kunos, G., & Leggio, L. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109809 · Cited by 16

A two-front nutritional environment fuels colorectal cancer: perspectives for dietary intervention

Alderweireldt, E., Grootaert, C., Wever, O. D., & Camp, J. V. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.11.002 · Cited by 16

Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis

Yin, J., Bao, L., Chen, R., Gao, W. Y., Gao, X., & Yao, W. (2018) · Biochimie · doi:10.1016/j.biochi.2018.05.020 · Cited by 16

Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis

Ye, X., Chen, Y., Qi, J., Zhu, S., Wu, Y., Xiong, J., Hu, F., Guo, Z., & Liang, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175811 · Cited by 14

Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children

Hua, M., Huang, J., Hu, C., Yao, T., & Lai, M. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00420 · Cited by 15

Fibroblast Growth Factor 21 Response in a Preclinical Alcohol Model of Acute-on-Chronic Liver Injury

Christidis, G., Karataylı, E., Hall, R. A., Weber, S. N., Reichert, M., Hohl, M., Qiao, S., Boehm, U., Lütjohann, D., Lammert, F., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157898 · Cited by 15

Chlorhexidine-containing chewing gum. Clinical documentation

Imfeld, T. N. (2006) · PubMed · doi:10.5167/uzh-2549 · Cited by 15

Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway

Liu, Z., Wei, S., Jiang, Y. Z., Su, W., Ma, F., Cai, G., Liu, Y., Sun, X., Lu, L., Fu, W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.003 · Cited by 15

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity

Luo, Y., Li, X., Ma, J., Abbruzzese, J. L., & Lu, W. (2021) · Cancers · doi:10.3390/cancers13040778 · Cited by 14

Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome

Siemienowicz, K. J., Furmanska, K., Filis, P., Talia, C., Thomas, J. L., Fowler, P., Rae, M. T., & Duncan, W. C. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111196 · Cited by 13

Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis

Nicholls, H. T., Hornick, J. L., & Cohen, D. E. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00379.2016 · Cited by 13

Raspberry Polyphenolic Extract Regulates Obesogenic Signals in Hepatocytes

Fotschki, B., Laparra, J. M., & Sójka, M. (2018) · Molecules · doi:10.3390/molecules23092103 · Cited by 14

Ascorbic acid attenuates cell stress by activating the�fibroblast growth factor 21/fibroblast growth factor receptor�2/adiponectin pathway in HepG2 cells

Gu, X., Luo, X. M., Wang, Y., He, Z., Li, X., Wu, K., Zhang, Y., Yang, Y., Ji, J., & Luo, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10457 · Cited by 13

Defects in mTORC1 Network and mTORC1-STAT3 Pathway Crosstalk Contributes to Non-inflammatory Hepatocellular Carcinoma

Li, T., Zhang, G.-H., Wang, L.-L., Li, S., Xu, X.-P., & Gao, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00225 · Cited by 9

Effects of lactic acid bacteria-containing foods on the quality of sleep: a placebo-controlled, double-blinded, randomized crossover study

Nakagawa, M., Yamamoto, H., Kawaji, M., Miura, N., Wakame, K., & Endo, T. (2018) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v8i12.572 · Cited by 12

Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development

Thapa, K., Grewal, A. S., Kanojia, N., Rani, L., Sharma, N., & Singh, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200121143959 · Cited by 12

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)

Kim, K., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072296 · Cited by 13

Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma

Vachher, M., Bansal, S., Kumar, B., Yadav, S., Arora, T. K., Wali, N. M., & Burman, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30252 · Cited by 11

Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients

Corbee, R. J., van Everdingen, D. L., Kooistra, H. S., & Penning, L. C. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1086987 · Cited by 11

Endocrine FGFs and their signaling in the brain: Relevance for energy homeostasis

Zangerolamo, L., Carvalho, M. U. W. B. D., Velloso, L. A., & Barbosa, H. C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176248 · Cited by 11

Expression of fibroblast growth factor 21 in patients with biliary atresia

Li, D., Lu, T., Shen, C., Liu, Y., Zhang, J., Shan, Y., Luo, Y., Xi, Z., Qiu, B., Chen, Q., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.03.003 · Cited by 11

Circulating fibroblast growth factor 21 in patients with liver cirrhosis

Krautbauer, S., Rein‐Fischboeck, L., Haberl, E. M., Pohl, R., Wiest, R., & Buechler, C. (2017) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0468-z · Cited by 11

Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets

Wu, D., & van de Graaf, S. F. J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116437 · Cited by 12

FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data

Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 11

Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment

Liang, C., Li, J., Tian, B., Tian, L., Liu, Y., Li, J., Xin, L., Wang, J., Fu, C., Shi, Z., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112298 · Cited by 12

Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease

Karamfilova, V., Assyov, Y. S., Nedeva, I., Gateva, A., Ivanova, I. D., Cherkezov, N., Mateva, L., & Kamenov, Z. A. (2021) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2021.201165 · Cited by 10

Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children

Sodhi, K., & Bracero, L. A. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000393 · Cited by 10

Practical prospects for boosting hepatic production of the “pro-longevity” hormone FGF21

McCarty, M. F. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0057 · Cited by 10

Controlled release of hydrogel-encapsulated mesenchymal stem cells-conditioned medium promotes functional liver regeneration after hepatectomy in metabolic dysfunction-associated steatotic liver disease

Kasahara, N., Teratani, T., Doi, J., Yokota, S., Shimodaira, K., Kaneko, Y., Ohzawa, H., Sakuma, Y., Sasanuma, H., Fujimoto, Y., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03993-w · Cited by 10

Th2 Cytokines Increase the Expression of Fibroblast Growth Factor 21 in the Liver

Kang, S., Lee, S. E., Choi, M., Chang, J.-Y., Kim, J.-T., Zhang, B., Kang, Y.-E., Lee, J. H., Yi, H., & Shong, M. (2021) · Cells · doi:10.3390/cells10061298 · Cited by 9

Citreoviridin induces triglyceride accumulation in hepatocytes through inhibiting PPAR-α in vivo and in vitro

Feng, C. J., Li, D., Jiang, L., Liu, X., Li, Q., Geng, C., Sun, X., Yang, G., Yao, X., & Chen, M. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.06.021 · Cited by 9

Association of the 3′UTR polymorphism (rs11665896) in the FGF21 gene with metabolic status and nutrient intake in children with obesity

Ruiz-Padilla, A. J., Morales-Hernandez, G., Ruíz‐Noa, Y., Alonso‐Castro, Á. J., Lazo-de-la-Vega-Monroy, M.-L., Preciado‐Puga, M. D. C., Rangel-Salazar, R., & Ibarra‐Reynoso, L. D. R. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0546 · Cited by 9

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation

Braun, L. R., Feldpausch, M. N., Czerwonka, N., Torriani, M., Grinspoon, S. K., & Stanley, T. L. (2017) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2017.10.002 · Cited by 9

Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta‐Analysis of Randomized Controlled Trials

Nie, Z., Xu, J., Liu, Y., Cao, Q., Qiu, X., Su, Y., & Han, S. (2025) · International Journal of Endocrinology · doi:10.1155/ije/9943228 · Cited by 8

Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6

Eckard, A. R., Hughes, H., Hagood, N. L., O’Riordan, M. A., Labbato, D. E., Kosco, J. C., Scott, S., & McComsey, G. A. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002285 · Cited by 8

Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet

Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B. W., Patterson, A. D., & Gonzalez, F. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.012 · Cited by 120

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Liu, C., Schönke, M., Spoorenberg, B., Lambooij, J. M., van der Zande, H. J. P., Zhou, E., Tushuizen, M. E., Andréasson, A., Park, A., Oldham, S. N., et al. (2023) · eLife · doi:10.7554/elife.83075 · Cited by 72

The ability of FGF21 to ameliorate signs of non-alcoholic fatty liver disease in mice depends on sex and diet

Balybina, N., En, M., Jakovleva, T., Kazantseva, A. Y., & Бажан, Н. М. (2026) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-26-88

Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice

Lin, D., Sun, Q., Liu, Z., Pan, J., Zhu, J., Wang, S., Jia, S., Zheng, M., Li, X., & Gong, F. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.087 · Cited by 37

[Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease].

Chen, L., Jiang, M., Xin, Y., Wang, J., Liu, Y., Jiang, X., & Xuan, S. (2016) · PubMed Central · doi:10.3760/cma.j.issn.1007-3418.2016.02.006